Hologic (HOLX)
(Delayed Data from NSDQ)
$79.29 USD
-1.20 (-1.49%)
Updated Nov 7, 2024 03:59 PM ET
After-Market: $79.32 +0.03 (0.04%) 5:54 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$79.29 USD
-1.20 (-1.49%)
Updated Nov 7, 2024 03:59 PM ET
After-Market: $79.32 +0.03 (0.04%) 5:54 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down
by Zacks Equity Research
Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.
Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?
by Zacks Equity Research
Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.
3 Plastic & Reconstructive Surgery Stocks Looking Good
by Zacks Equity Research
Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.
Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval
by Zacks Equity Research
Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.
Hologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Hologic (HOLX) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic (HOLX) Launches Brevera, Progresses in Breast Health
by Zacks Equity Research
Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.
Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance
by Zacks Equity Research
Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.
MedTech Stock Earnings Slated for Aug 2: CAH, HOLX & More
by Zacks Equity Research
Despite solid strategic initiatives, the ongoing political conundrum at the Capitol Hill is likely to affect earnings results of these four major Medical Technology bigwigs.
What's in the Offing for Hologic (HOLX) in Q3 Earnings?
by Zacks Equity Research
Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical
Hologic (HOLX) Product Pipeline Strong, Competition Rife
by Zacks Equity Research
On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.
Hologic (HOLX) Gets FDA Clearance for Aptima HSV 1 & 2 Test
by Zacks Equity Research
Hologic, Inc. (HOLX) recently received FDA approval for the commercial launch of the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system.
Hologic Receives Extended FDA Clearance for SculpSure in US
by Zacks Equity Research
Hologic, Inc. (HOLX) declared that the company's subsidiary Cynosure has received FDA's expanded clearance for SculpSure.
Hologic (HOLX) Up 3.5% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Hologic Wins FDA Approval for Genius 3D Mammography Exam
by Zacks Equity Research
Hologic, Inc. (HOLX) continues to expand its Breast and Skeletal Health business through innovation and product development.
Envision (EVHC) Acquires Gwinnett Emergency Specialists
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) announced the acquisition of Gwinnett Emergency Specialists, P.C.
Halyard Health (HYH) Expands CORGRIP System Product Line
by Zacks Equity Research
Halyard Health (HYH), a leading medical technology company, recently announced the expansion of its CORGRIP Nasogastric/Nasointestinal Tube Retention System product line.
Hologic (HOLX) Poised on Balanced Growth Amid Currency Woes
by Zacks Equity Research
On May 23, we issued an updated research report on Bedford, MA-based Hologic Inc. (HOLX).
Integra Lifesciences Hits 52-Week High on Product Launches
by Zacks Equity Research
Share price of Plainsboro NJ-based Integra Lifesciences Corporation (IART) reached a new 52-week high of $47.50 on May 19, finally closing a tad lower at $47.39.
Quest Diagnostics Poised on Solid Q1 Results Despite Woes
by Zacks Equity Research
On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.
Intuitive Surgical at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Sunnyvale, CA-based Intuitive Surgical Inc (ISRG) scaled a new 52-week high of $874.54 on May 19, eventually closing a bit lower at $870.33.
Quality Systems (QSII) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported fourth-quarter fiscal 2017 adjusted earnings of 18 cents per share, exceeding the Zacks Consensus Estimate by a penny. Earnings remained flat on a year-over-year basis.
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
by Zacks Equity Research
Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.
McKesson (MCK) Beats Earnings Estimate in Q4, Revenues Miss
by Zacks Equity Research
McKesson Corporation (MCK) reported fourth-quarter fiscal 2017 earnings of $3.39 per share, beating the Zacks Consensus Estimate of $3.04.
Halyard Health-Sustainable Solutions Ink License Agreement
by Zacks Equity Research
Halyard Health (HYH) announced a new license and supply agreement with Sustainable Solutions. The license agreement is aimed at converting recycled HALYARD Wrap into an environment friendly product for healthcare facilities.